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We assessed the quality of life (QOL) of patients with epilepsy using the Quality of Life in Epilepsy Inventory (QOLIE-31).
As the first step we compared our results with the data from an American survey in order to validate the test in Hungary.
The results show that the Hungarian values were lower but that they followed the same trends as the American data. There
was only one controversial result in the question-group of the ‘the effects of treatment’, which could be explained by the
differences in habits and conventions, opportunities and expectations between Hungarian and American epileptic patients. We
found significant differences in many aspects of quality of life with respect to (a) gender (general quality of life, seizure worry),
(b) pharmacological treatment form (cognitive functions, medication effects, total score and social and role functioning) and
(c) economic activity of patients (cognitive functions, emotional well-being, energy/fatigue, medication effects, overall quality
of life, overall scores, seizure worry, social and role functioning). We have tried to explain the differences found by taking either
the characteristics of epilepsy or the social background of the epileptic patient into consideration. Based on previous knowledge
we have tried to define the situations where the assessment of quality of life for people with epilepsy, may be beneficial to their
core.
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INTRODUCTION
Epilepsy is one of the most common chronic neurolog-
ical diseases, which in the majority of the cases affects
patients throughout their life. Doctors usually measure
the effects of the complex pharmaco–psycho-social
therapy based on the frequency of the seizures and
the side effects of the antiepileptic drugs. However,
these parameters do not show the exact influence of
the illness on the lifestyle and feelings of the patients.
This real effect of a complex therapy can only be mea-
sured by holistic methods, by changes in the patients’
feelings, the change of their mental and physical pow-
ers and of their social adaptation. All these complex
changes can be mapped by the questionnaire of the
quality of life adapted to epileptic disease1–11. The re-
sults of these different examinations are not exactly
concordant and the opinions of the investigators differ
regarding the situations in which the use of the ques-
tionnaire of quality of life is recommended in clinical
practice2, 11–16.
The aim of this survey was to:
• Find a questionnaire which could be easily com-
pleted (QOLIE-31).
• Adapt it for use in our country.
• Validate it.
• Compare the results to those of the US population.
• Evaluate some hypotheses and discuss some inter-
esting data obtained from the first Hungarian sur-
vey concerned with QOL in patients with epilepsy.
• Define situations where the application of the
QOLIE 31 may be beneficial to the daily routine
of patients.
MATERIALS AND METHODS
The study was performed in five Hungarian Epilepsy
Centres (SOTE-Clinic of Psychiatry and Psychother-
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Table 1: Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Epilepsy Diagnosis completed Uncertain
Age More than 16 years Less than 16 years
Gender Both
Controls/visits Regular Irregular
Other illness None in the last 6 months Have had in the last 6 months
Complete the questionnaire Without help Only with help
Therapy No change in last 6 months Change in last 6 months
Written consent Yes No
apy, Central Military Hospital. Budapest; County Hos-
pital, Miskolc; Town Hospital, Miskolc, Neurologi-
cal Clinic of Medical University, Debrecen) and in-
volved the survey of 185 patients. The QOLIE-31
questionnaire was used. The questionnaire was trans-
lated by two colleagues caring for epileptic patients.
They compared and interpreted the translation and
also asked for the opinion of a third independent
expert. Prior to the studies the epileptic population
(15 patients) filled in the questionnaire under the con-
trol of the attending physician and the opportunity was
given to discuss any problems that arose. The Hungar-
ian patients understood the content of all of the ques-
tions, therefore no alterations were needed.
170 completed questionnaires were adequate for
analysis. The attending physicians who regularly con-
trolled the patients conveyed the clinical data of each
patient to us. The inclusion and exclusion criteria were
summarized according to the aspects shown in Table 1.
The patients were divided into different groups on the
basis of the type and severity of their illness. This clas-
sification was similar to that of the original survey per-
formed in the USA17. The severity was defined by the
seizure frequency in the year before the patients were
included in the study. The patients were divided into
four groups; seizure-free, low, moderate and high fre-
quency of seizures (see Table 2). We had a special
group of 18 patients, who were examined after their
first epileptic seizure. They were included in the study
on the basis of very strict criteria. Only those patients
for whom the occurrence of the epileptic seizure could
be proved, e.g. the lack of a witness would exclude the
patient, could be enrolled. This explains the low num-
ber of the patients in this group and therefore statistical
analysis was performed separately for this group.
The QOLIE-31 inventory for epileptic patients was
used, but some questions were changed in order to sur-
vey the patients with new onset epilepsy (see Table 3).
During the analysis of the QOLIE-31 inventory, the
values of the individual question-groups as well as the
overall score were determined16. The determination
of the factors on the questionnaire that influence the
quality of life are carried out with the aid of scales.
The patient gives the value—as the answer—which is
nearest to his/her feelings and state. All scale scores
were transformed linearly into scales of 0–100, with
higher values representing better functioning and well-
being. Using this method it is possible to treat the dis-
tinct question-groups separately. The QOLIE-31 over-
all score can be derived by weighting and summing
QOLIE-31 scale scores16.
The data analysis consisted of different aspects; gen-
der, economic activity, therapy-type and severity. The
statistical analysis was performed using the Kruskal–
Wallis method and the results were qualified at the
95% probability level.
RESULTS
The averages for the Hungarian patients of all
question-groups of the QOLIE-31 inventory were
compared to the data of the same questionnaire used in
the USA17. Generally, the total scores of the identical
question-groups were lower for the Hungarian popu-
lation than in the USA. The SD (standard deviation)
did not show a significant difference between the two
assessments, as shown in Table 4. The greatest differ-
ence between the two populations was found in the
question-group ‘overall quality of life’, and ‘social and
role functioning’ (USA: 67.17; H: 55.45; USA: 67.25,
H: 56.88).
The averages of the question-group ‘cognitive func-
tions’ were the same (USA: 59.96; H: 59.26). With
respect to the results of the question-group ‘effects
of medication’ the views of the Hungarian patients
were more optimistic (USA: 55.34; H: 57.39). In the
other question groups the greatest difference consisted
of about 10 points (on average the Hungarian patient
scores were 8.19 in the negative direction compared to
the US scores). The scale of the differences between
these question groups, when compared to the positive
difference is important.
We found the same tendency when comparing the
results of the QOLIE-31 according to seizure severity.
(see Table 5). The results in Table 6 illustrate that the
greatest difference was found between the seizure-free
groups of Hungary and the USA.
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Table 2: The severity of epilepsy according to seizure frequency of different types of seizures17.
Seizure-free Low Moderate High
Generalized tonic–clonic 0 1 2–4 <5
Simple- and complex partial 0 1–4 5–12 <13
Other forms 0 1–2 3–12 <13
Table 3: Modification to the wording of the original QOLIE-31
items for the new onset patient group.
No. of items QOLIE-31 Modified
24 How worried are
you that the
medications you
are taking will be
bad for you if
taken for a long
time?
How worried are you that
you will have to take a
drug for a prolonged
period of time in the
future?
29 How bothered




How bothered are you
about the recommended










How bothered are you
about the recommended
changes to your life style?
To control the reliability of the questionnaire we
have chosen two very simple, but in clinical practice
very important, conditions as null hypothesis, namely
(a) patients on monotherapy, and (b) patients actively
working, have a better quality of life. Analysing our
data according to the applied therapy, we obtained the
following results. The results in Table 7 illustrate that
there was a significant difference between the group
on monotherapy and the group on bitherapy with re-
spect to ‘cognitive function’ (P = 0.0212), ‘social
activity’ (P = 0.0007) and ‘overall quality of life’
(P = 0.0073). We did not find significant differences
between the group on bitherapy and the group on poly-
therapy.
In the evaluation based on economic activity, shown
in Table 8, it can be seen that the quality of life of
patients on disability pension was worse that that of
the actively working patients. (Cognitive functions:
P = 0.0010; emotional well-being: P = 0.00001;
energy/fatigue: P = 0.0116; medication effects: P =
0.0070; overall quality of life: P = 0.0000; seizure
worry: P = 0.0064; social and role functioning: P =
0.0001).
The results of the evaluation according to gender
are shown in Table 9. The perceptions of the women
were usually more pessimistic than those of the men
in most question-groups, with the exceptions of cog-
nitive functions and social functioning. Significant dif-
ference was found between the genders regarding the
averages of ‘overall quality of life’ (P = 0.0101) and
‘seizure worry’ (P = 0.0021).
The population participating in this survey had a
very special group, namely the 18 patients who were
examined after their first epileptic seizure. They com-
pleted the questionnaires after they had been informed
about the possible limitations they could expect after
the first fit. (These being seizure recurrence and the
development of epileptic disease and the transitory re-
strictions necessary in the year following the seizure,
e.g. prohibition of vehicle driving and of the perfor-
mance of dangerous work.)
We compared the results of the questionnaires of
this group with those of the seizure-free patients sub-
jected to continuous antiepileptic treatment. The av-
erages of the question-groups were usually higher in
the group of patients after the first seizure, with the
exception of ‘overall quality of life’ and ‘social func-
tioning’. As shown in Table 10, significant differences
were found in three question-groups; ‘cognitive func-
tions’ (P = 0.0130), ‘energy/fatigue’ (P = 0.017),
and ‘social functioning’, with the greatest difference
appearing in the latter. Patients after the first seizure
viewed their social activity more negatively than the
seizure-free patients (P = 0.000).
DISCUSSION
We have carried out a survey aimed at assessing the
quality of life of patients in five epilepsy centres in
Hungary, using the QOLIE-31 inventory. As the first
step we compared our results with data from a survey
in the USA (Devinsky et al. 1995), in order to vali-
date the questionnaire in our country. Our results have
shown that for the QOLIE-31 inventory overall scores
in Hungary are generally lower, but that they change
in parallel with the American data. The tested pop-
ulation in Hungary perceived their quality of life as
worse in all question-groups compared to the popula-
tion coping with similar disease in the USA. We ex-
plain the lower overall score (the negative judgement)
by the difference in economic and social status and by
the difference in both the social judgement and ability
to cope with the disease. The greatest difference was
found in two question-groups, namely in the overall
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Table 4: Summarized data of the questionnaire collected in the USA and in Hungary according to the groups of questions.
QOLIE-31 (USA): n = 304; QOLIE-31 (H): n = 170; calculated with the Moiser formula.
Average
Number of questions QOLIE-31 USA (SD) QOLIE-31 H (SD)
Seizure worry 5 58.29 (±25.76) 53.95 (±28.53)
Overall quality of life 2 67.17 (±18.38) 55.45 (±19.32)
Emotional well-being 5 67.2 (±19.28) 58.28 (±18.48)
Energy/fatigue 4 55.3 (±21.10) 49.68 (±17.68)
Medication effects 3 55.34 (±30.52) 57.39 (±31.13)
Social & role functioning 5 67.25 (±26.88) 56.88 (±23.60)
Table 5: Summarized data of the questionnaire collected in the USA and in Hungary.
Seizure-free Low Moderate High
H USA H USA H USA H USA
N (%) = 50 (29) 21 (6) 23 (13) 116 (38) 36 (21) 136 (44) 61 (35) 31 (10)
Overall quality of life 62.24 72.00 67.00 68.10 57.66 65.80 56.32 65.90
Seizure worry 53.78 74.90 62.12 61.40 52.22 53.10 52.97 57.40
Emotional well-being 59.92 73.40 61.40 68.50 60.13 64.90 57.54 68.10
Energy/fatigue 47.86 63.00 53.75 53.60 48.44 56.40 53.16 50.50
Cognitive functions 62.10 70.75 60.86 63.90 57.48 59.35 58.13 61.15
Effects of medication 59.58 56.80 60.42 59.80 59.03 52.70 55.41 49.10
Social functioning 65.74 77.70 62.95 73.10 52.63 62.00 52.67 58.20
quality of life and in social and role functioning, where
the difference was greater than 10%. As the study used
for comparison did not provide sufficient information
we were unable to perform statistical analysis on the
data. Thus, only the ratio of the differences could be
calculated and used for numerical comparison. Com-
paring the values according to seizure severity, in the
seizure-free group we found more than 10% difference
in four question-groups, namely in ‘seizure worry’,
‘emotional well-being’, ‘energy/fatigue’ and in ‘social
functioning’. In the other groups a greater difference,
exceeding 10%, was found in only one question group,
the group of low seizure frequency, where the differ-
ence with respect to social functioning was 10, 15%.
The results shown in Table 6 indicate that in our coun-
try the people with seizure free epilepsy suffer more
from prejudices than seizure free patients in the USA.
Comparing the data of the Hungarian and American
surveys we found an opposite trend, in terms of neg-
ative and positive scoring in only one question-group,
namely in the judgement of the effects of treatment.
The Hungarian patients perceived this more positively.
Although when comparing the data we were unable to
calculate statistical significance, we felt that this posi-
tive difference was worthy of an explanation. This re-
sult may be explained by the different mental health
expectations, the difference in the expected efficacy of
treatment, the confidence in doctors and by the differ-
ent circumstances and different opportunities open to
the two populations. We found a similar trend when
comparing the QOLIE-31 survey results of patients
experiencing different seizure severity, but the values
were lower than 10% in all cases.
The above-mentioned data may indicate that be-
cause of their disease the Hungarian patients, com-
pared with the American study population, judge
themselves to be at a greater disadvantage with respect
to their social status. This is why they have greater
confidence in the doctors and the treatment.
If we compare the two epileptic populations accord-
ing to the severity of the seizures, we can see that the
relative number of the patients in each group is differ-
ent (see Table 5). In the Hungarian population there are
more patients in the seizure-free group (H: 29%, USA:
6%) and in the high frequency seizure group (H: 35%,
USA: 10%).
When considering these differences, the more
negative perception of their quality of life by the Hun-
garian epileptic population can be more easily under-
stood. When evaluating data according to gender, we
found significant difference in the judgement of ‘over-
all quality of life’ and of ‘seizure worry’ between
men and women. Other surveys reported similar re-
sults with adolescents suffering from epilepsy. The
girls showed more anxiety, less happiness and more
negative attitudes towards epilepsy18. Our results re-
flect the social judgement and the living conditions
of women in Hungary, i.e. women are at a greater
disadvantage at their place of employment compared
to men. A Hungarian survey, carried out on the nor-
mal population, showed similar results19. The role of
women in their work and their family life may be ac-
104 J. La´m et al.
Table 6: Comparison of the American and Hungarian values of the question-groups from the seizure-free patients. The
differences were greater in almost every question-group by more than 10%.
Seizure-free
H (50) USA (21) Difference (%)
Seizure worry 53.78 74.90 21.12
Overall quality of life 62.24 72.00 9.76
Emotional well-being 59.92 73.40 13.48
Energy/fatigue 47.76 63.00 15.24
Cognitive functions 62.10 70.75 8.65
Medication effects 59.58 56.80 −2.78
Social and role functioning 65.74 77.70 11.96
Table 7: Comparison of values concerning mono- bi- and polytherapy.
Groups of questions Monotherapy (SD) Bitherapy (SD) Polytherapy (SD) Difference between mono- and bitherapy
N = 89 53 27
Cognitive functions 62.53 (±19.33) 55.35 (±19.17) 55.56 (±24.19) 7.18a
Emotional well-being 60.14 (±18.10) 55.15 (±17.65) 56.44 (±20.59) 4.99
Energy/fatigue 50.11 (±17.19) 50.29 (±19.59) 47.78 (±13.37) −0.18
Medication effects 61.85 (±31.36) 49.63 (±28.65) 54.11 (±32.49) 12.22a
Overall quality of life 62.07 (±21.91) 55.48 (±19.64) 52.96 (±24.86) 6.59
Overall score 60.21 (±16.53) 52.88 (±15.33) 53.26 (±19.96) 7.33b
Seizure worry 56.73 (±29.56) 51.14 (±26.18) 47.33 (±29.88) 5.59
Social and role
functioning 62.9 (±22.10) 48.98 (±22.78) 53.58 (±26.92) 13.92b
a P < 0.05 and b P < 0.01.
companied by great tension. Although women are not
at all equal to men on the manpower market, they all
want to work because they feel it is important that they
too should earn money (this dates from the tradition
of the previous era when it was proclaimed that those
who had no working place should not eat). At the same
time women working in a city, in trade or in industry,
are at a disadvantage as employees. If they are suf-
fering from an incurable disease finding employment
is nearly impossible. Those who work in households
or in agriculture run counter to social prejudices. It is
a further handicap that society and health authorities
view this illness to be a special disadvantage in mar-
riage and in the building of a family (the majority of
people interviewed were at the reproductive age). So,
they have had to cope with all those problems, which
cause concern to healthy young people, and they also
have to cope with their illness. This period of life is
difficult for all women and it is especially difficult for
women with epilepsy. The facts described above help
us to explain the differences between the two genders
found in our study.
To control the efficacy of the QOLIE-31 inventory,
we used a null-hypothesis according to which epileptic
patients on monotherapy have a better quality of life
than those treated with more than one medication. The
results of the study confirmed our hypothesis, since we
found significant differences between the patients on
mono- and on bitherapy in three question-groups (see
Table 7). A deviation was found in cognitive functions
and indicated the adverse effects of the drugs, which
appear to increase the more drugs are used. Medica-
tion effects were also significantly different between
the two groups. This indicates that in these cases the
epilepsy of patients was well controlled by monother-
apy.
These two facts explain the more positive perception
of the quality of life by the patients on monotherapy.
Of course the patients well controlled by monotherapy,
with less adverse effects, have better cognitive func-
tions and are socially more active and this explains
their more positive perception of their ‘social and role
functioning’20. We also analysed and compared the
bitherapy and polytherapy groups, but no significant
differences were found between them21, 22.
Another null-hypothesis was used for analysis, ac-
cording to which the patients conducting an active
life can work and have a better quality of life than
the disabled ones. Our results showed that after com-
paring the group of epileptic patients who were em-
ployed with those who were disabled, their percep-
tions of quality of life were very different. In all
question-groups we found significant deviations (see
Table 8)20, 23.
Unfortunately, in our country a problem-solving
mechanism is functioning, according to which those
epileptic patients who are able to work, do not have
the opportunity to work and instead become pensioned
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Table 8: Answers to the questions on economic activity.
Difference Difference Difference
active active active
Groups of questions Active (SD) Unemployed (SD) Disabled (SD) OAP (SD) unemployed disabled OAP
N = 33 14 62 13
Cognitive functions 64.71 (±17.42) 66.60 (±19.26) 51.54 (±20.70) 51.58 (±26.76) −1.89 13.17b 13.13
Emotional well-being 65.36 (±14.67) 64.00 (±15.13) 50.45 (±16.93) 50.15 (±28.12) 1.36 14.91b 15.21
Energy/fatigue 52.55 (±15.67) 55.36 (±15.38) 44.03 (±17.90) 48.85 (±20.12) −2.81 8.52b 3.7
Medication effects 64.01 (±32.03) 61.70 (±33.45) 49.06 (±28.72) 54.70 (±33.79) 2.31 14.95b 9.31
Overall quality of life 67.13 (±18.61) 65.36 (±20.98) 50.00 (±19.71) 51.15 (±30.70) 1.77 17.13b 15.98
Overall score 62.96 (±12.83) 63.46 (±15.34) 48.46 (±16.24) 51.49 (±22.90) −0.5 14.5b 11.47
Seizure worry 59.22 (±26.30) 64.19 (±27.68) 44.66 (±29.50) 50.05 (±25.73) −4.97 14.56b 9.17
Social and role functioning 63.45 (±23.18) 62.36 (±26.18) 45.95 (±21.33) 54.15 (±22.60) 1.09 17.15b 9.3
OAP: old age pensioner.
b P < 0.01.
Table 9: Comparison of the values, calculated on the basis of the distribution according to gender.
Male (SD) Female (SD) Difference
Group of questions 90 80
Cognitive functions 59.21 (±21.01) 59.31 (±19.47) −0.1
Emotional well-being 60.72 (±18.60) 55.60 (±18.08) 5.12
Energy/fatigue 50.54 (±17.82) 47.48 (±17.43) 3.92
Medication effects 60.93 (±28.94) 53.50 (±33.12) 7.43
Overall quality of life 63.31 (±20.74) 54.26 (±22.47) 9.05a
Overall scores 58.72 (±17.77) 55.24 (±16.04) 3.48
Seizure worry 60.26 (±28.44) 47.03 (±27.16) 13.23a
Social and role functioning 56.88 (±24.26) 58.04 (±23.94) −1.16
a P < 0.01.
Table 10: Comparison the values of the seizure-free and first seizure groups.
Seizure-free (SD) First seizure Difference
N = 50 18
Seizure worry 53.78 (±23.10) 57.33 (±23.37) −3.50
Overall quality of life 62.24 (±21.19) 60.14 (±19.73) +2.1
Emotional well-being 59.92 (±15.99) 66.44 (±17.52) −6.52
Energy/fatigue 47.86 (±16.68) 59.17 (±17.17) −11.31a
Cognitive functions 62.10 (±19.58) 75.65 (±14.01) −15.73a
Medication effects 59.58 (±30.63) 62.96 (±19.73) −3.38
Social and role functioning 65.74 (±22.47) 34.99 (±14.97) +30.75a
a P < 0.01.
off, disabled, contrary to European practice24. This in-
cites us to work against this solution and fight for the
possibility that active epileptic patients obtain employ-
ment and conduct an active life.
A special question is raised in our work: what does
the first epileptic seizure mean for the patient? We
would like to know how the patients perceive the im-
pact of the seizure on their quality of life. Although the
number of patients in the group was low, we feel the
differences found are important. Comparing the aver-
ages of the test performed on the seizure free group
with those obtained after the first seizure, we found
a significant difference between the two groups in
‘cognitive functions’ and in ‘social functioning’. Of
course, after the first seizure the patients perception
of their cognitive functions was better, because they
had not been on medication and therefore no side ef-
fects had manifested themselves21, 22. The values ob-
tained in the question group of ‘social functioning’
were very low for patients after the first seizure. These
results highlight the fact that the occurrence of the first
epileptic seizure constitutes a considerable psycholog-
ical problem for the patients. Uncertainty (the observa-
tion time), and the fear of reoccurrence of the seizure
may cause deterioration of their quality of life. It ap-
pears that after the first epileptic seizure we have to
apply a short psycho-educational or psychotherapeutic
treatment in order to maintain the quality of life22, 24.
In the initial phase of epilepsy and the case of isolated
seizures the quality of life evaluation of patients also
appears to be important in order to confirm the ob-
tained data.
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The survey of the patients’ actual life-situation and
of the medical and social outcome made it possible
to assess the information obtained by the use of the
QOLIE-31 inventory in the care of epileptic patients.
In the following we list those life-situations in which
a short evaluation of quality of life may be important
for planning the optimal therapy and provide useful
information for the attending physicians:
• At the beginning of the disease (see data of the
patients after the first seizure).
• During continuous therapy, when the patient is in
steady state, the overall score of the questionnaire
may provide information on the patient’s capacity
to cope with the disease.
• When changing the therapy, in order to measure
the effect of the new therapy.
• In the special biological situations of life (pu-
berty, pregnancy, menopause), to obtain informa-
tion about their impact on our patients.
• We can measure the effects of positive or negative
situations of life (finishing school, beginning an
independent life, child birth, marriage, travelling,
and conversely: unemployment, divorce, death in
the family etc.).
• For the perception of the different problems of
epilepsy was may be able to answer some ques-
tions: what we have to do, e.g. in case of therapy-
resistance, seizure-caused lesion, before and after
epilepsy surgery, etc.10, 18
On the basis of our preliminary investigation, the
QOLIE-31 inventory and its modified version for test-
ing patients with epilepsy and after the first epileptic
seizure, may help us in achieving the mentioned goal.
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